论文信息 - Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial - 字舞流文

Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial

R. Motzer | K. Pittman | E. Esteban | B. Escudier | G. Bjarnason | H. Lim | A. Niethammer | Ho Yeong Lim | S. Hariharan | D. Lu | T. Hutson | P. Senico